0001643918-19-000003.txt : 20191107 0001643918-19-000003.hdr.sgml : 20191107 20191107164849 ACCESSION NUMBER: 0001643918-19-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191107 DATE AS OF CHANGE: 20191107 EFFECTIVENESS DATE: 20191107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Midatech Pharma Plc CENTRAL INDEX KEY: 0001643918 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-352895 FILM NUMBER: 191201057 BUSINESS ADDRESS: STREET 1: ODDFELLOWS HOUSE STREET 2: 19 NEWPORT ROAD CITY: CARDIFF STATE: X0 ZIP: CF24 0AA BUSINESS PHONE: 44 (0)1235 888300 MAIL ADDRESS: STREET 1: ODDFELLOWS HOUSE STREET 2: 19 NEWPORT ROAD CITY: CARDIFF STATE: X0 ZIP: CF24 0AA D 1 primary_doc.xml X0708 D LIVE 0001643918 Midatech Pharma Plc ODDFELLOWS HOUSE 19 NEWPORT ROAD CARDIFF X0 UNITED KINGDOM CF24 0AA 44 1235 888300 UNITED KINGDOM None None Corporation true Craig Cook Oddfellows House 19 Newport Road Cardiff X0 UNITED KINGDOM CF24 OAA Executive Officer Director Stephen Stamp Oddfellows House 19 Newport Road Cardiff X0 UNITED KINGDOM CF24 OAA Executive Officer Director Frederic Duchesne Oddfellows House 19 Newport Road Cardiff X0 UNITED KINGDOM CF24 OAA Director Huaizheng Peng Oddfellows House 19 Newport Road Cardiff X0 UNITED KINGDOM CF24 OAA Director Simon Turton Oddfellows House 19 Newport Road Cardiff X0 UNITED KINGDOM CF24 OAA Director Sijmen de Vries Oddfellows House 19 Newport Road Cardiff X0 UNITED KINGDOM CF24 OAA Director Rolf Stahel Oddfellows House 19 Newport Road Cardiff X0 UNITED KINGDOM CF24 OAA Director Biotechnology Decline to Disclose 06b false 2019-10-22 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Ave New York NY NEW YORK 10022 NY NEW YORK false 3000000 3000000 0 The total offering amount includes the concurrent registered offering of American Depositary Shares. false 1 210000 0 Sales commission relates to the sale of ADSs in the concurrent registered offering. HCW is also entitled to expense reimbursement up to $25,000, a 1% mgmt. fee and warrants to purchase an aggregate of 150,000 ADSs exercisable at $1.25 per ADS for 5 years. 0 false Midatech Pharma Plc Stephen Stamp Stephen Stamp Chief Financial Officer 2019-11-07